Douglas Lane & Associates’s Zimmer Biomet ZBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$41.1M Buy
477,780
+2,690
+0.6% +$236K 0.56% 73
2026
Q1
$43M Buy
475,090
+14,912
+3% +$1.37M 0.62% 68
2025
Q4
$41.4M Buy
460,178
+28,818
+7% +$2.73M 0.57% 77
2025
Q3
$42.5M Buy
431,360
+29,011
+7% +$2.87M 0.59% 72
2025
Q2
$36.7M Sell
402,349
-20,954
-5% -$2.03M 0.53% 73
2025
Q1
$47.9M Buy
423,303
+21,095
+5% +$2.26M 0.71% 57
2024
Q4
$42.5M Sell
402,208
-14,085
-3% -$1.51M 0.6% 71
2024
Q3
$44.9M Sell
416,293
-36,705
-8% -$4.01M 0.62% 66
2024
Q2
$49.2M Sell
452,998
-62,355
-12% -$7.35M 0.7% 55
2024
Q1
$68M Sell
515,353
-34,703
-6% -$4.33M 0.96% 40
2023
Q4
$66.9M Sell
550,056
-53,961
-9% -$6.02M 1.03% 37
2023
Q3
$67.8M Sell
604,017
-22,027
-4% -$2.8M 1.14% 38
2023
Q2
$91.2M Sell
626,044
-15,685
-2% -$2.13M 1.47% 16
2023
Q1
$82.9M Sell
641,729
-8,932
-1% -$1.12M 1.38% 20
2022
Q4
$83M Sell
650,661
-319
-0% -$37K 1.39% 22
2022
Q3
$68.1M Buy
650,980
+11,930
+2% +$1.31M 1.26% 30
2022
Q2
$67.1M Buy
639,050
+29,366
+5% +$3.48M 1.14% 36
2022
Q1
$78M Buy
609,684
+41,230
+7% +$4.97M 1.1% 34
2021
Q4
$70.1M Buy
568,454
+54,699
+11% +$7.16M 0.93% 38
2021
Q3
$73M Buy
513,755
+28,868
+6% +$4.25M 1.04% 31
2021
Q2
$75.7M Buy
484,887
+6,715
+1% +$1.09M 1.06% 35
2021
Q1
$74.3M Buy
478,172
+5,832
+1% +$903K 1.15% 32
2020
Q4
$70.7M Sell
472,340
-435
-0.1% -$61.4K 1.18% 33
2020
Q3
$62.5M Buy
472,775
+26,988
+6% +$3.53M 1.24% 28
2020
Q2
$51.7M Buy
445,787
+22,432
+5% +$2.58M 1.11% 39
2020
Q1
$41.5M Buy
423,355
+24,993
+6% +$3.28M 1.09% 37
2019
Q4
$57.9M Buy
398,362
+35,745
+10% +$4.93M 1.08% 40
2019
Q3
$48.3M Buy
362,617
+81,737
+29% +$10.6M 0.96% 47
2019
Q2
$32.1M Buy
280,880
+228,162
+433% +$26.7M 0.63% 62
2019
Q1
$6.54M Buy
+52,718
New +$5.99M 0.14% 106
2016
Q3
Sell
-4,057
Closed -$474K 218
2016
Q2
$474K Sell
4,057
-124
-3% -$14K 0.01% 174
2016
Q1
$433K Buy
+4,181
New +$404K 0.01% 179

Other funds holding ZBH

Douglas Lane & Associates's ZBH Position: Q2 2026 in Review

Douglas Lane & Associates increased its Zimmer Biomet (ZBH) stake by 0.57% in Q2 2026, buying an estimated $236K and bringing the position to 477,780 shares worth $41.1M. The position accounts for 0.56% of the portfolio, ranked #73.

Douglas Lane & Associates first reported a position in ZBH in Q1 2016 and has held it in 32 quarters since. The position peaked at $91.2M in Q2 2023. 906 funds tracked by Wall St. Rank hold ZBH as of Q2 2026.

  • Douglas Lane & Associates held 477,780 shares of Zimmer Biomet worth $41.1M as of Q2 2026.
  • Douglas Lane & Associates bought 2,690 Zimmer Biomet shares in Q2 2026, an estimated $236K.
  • Zimmer Biomet made up 0.56% of Douglas Lane & Associates's portfolio in Q2 2026, its #73 holding.
  • Douglas Lane & Associates first reported a position in Zimmer Biomet in Q1 2016 and has held it in 32 quarters since.
  • Douglas Lane & Associates's Zimmer Biomet position peaked at $91.2M in Q2 2023.
  • 906 funds tracked by Wall St. Rank held Zimmer Biomet as of Q2 2026.

Based on Douglas Lane & Associates's 13F filing for Q2 2026, filed 14 Jul 2026.